Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $44.8 million.

  • Aclaris Therapeutics' Total Non-Current Liabilities rose 613.36% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 613.36%. This contributed to the annual value of $56.1 million for FY2024, which is 6479.46% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Total Non-Current Liabilities of $44.8 million as of Q3 2025, which was up 613.36% from $46.9 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Total Non-Current Liabilities ranged from a high of $56.1 million in Q4 2024 and a low of $18.0 million during Q2 2024
  • For the 5-year period, Aclaris Therapeutics' Total Non-Current Liabilities averaged around $30.1 million, with its median value being $25.5 million (2021).
  • Per our database at Business Quant, Aclaris Therapeutics' Total Non-Current Liabilities crashed by 3631.74% in 2022 and then skyrocketed by 15989.25% in 2025.
  • Aclaris Therapeutics' Total Non-Current Liabilities (Quarter) stood at $25.5 million in 2021, then decreased by 6.26% to $23.9 million in 2022, then soared by 42.52% to $34.0 million in 2023, then surged by 64.79% to $56.1 million in 2024, then dropped by 20.04% to $44.8 million in 2025.
  • Its Total Non-Current Liabilities was $44.8 million in Q3 2025, compared to $46.9 million in Q2 2025 and $45.0 million in Q1 2025.